• Biologics
    • Modalities
      • Mammalian
      • Microbial
      • ADCs / Bioconjugates
      • mRNA / LNP
      • Drug Product
    • Technologies & Products
      • Expression Technologies
      • Discovery Products
      • Bioprocessing Products
    • Discovery and Preclinical
      • Early De-risking & Optimization
      • Cell Line & Strain Development
      • Process Development & Optimization
      • Analytical Development
      • Formulation Development
      • Non-GMP Manufacture
    • Clinical and Commercial
      • Process Development & Optimization
      • Formulation Optimization
      • cGMP Drug Substance Manufacture
      • cGMP Drug Product Manufacture
    Technical Support
    Regulatory Support
    View all locations
    View all Biologics offerings
    Woman and microscope

    Knowledge Center

    View all the latest resources available on site


    Visit our Knowledge Center

  • Small Molecules
    • Services
      • Drug Substance (API)
      • Particle Engineering
      • Drug Product
    • Technologies
      • Highly Potent API (HPAPI)
      • ADCs
      • Spray Dried Dispersions
      • Micronization & Jet Milling
      • Inhaled Delivery (DPI)
    • Solutions
      • Early Phase API
      • Commercial Production API
      • Bioavailability Enhancement
      • Integrated Offerings
    • Knowledge Center
      • Webinars
      • Presentations
      • Publications
      • Meet the Experts
      • View all
    View all Small Molecules offerings
    View all locations
    Clinical drug development & preformulation

    Knowledge Center

    View all the latest resources


    Visit our Knowledge Center

  • Cell & Gene
    • Services
      • Process Development
      • cGMP Manufacturing
      • Regulatory Consulting
      • Bioassay Services
      • Tissue Acquisition
    • Modalities
      • Autologous
      • Allogeneic
      • Viral Vectors
      • iPSCs
      • Exosomes
    • Technologies
      • MODA® Platform
      • Cocoon® Platform
      • Nucleofector® Technology
      • TheraPEAK® Media
      • Endotoxin and Pyrogen Testing
    • Knowledge Center
      • Peer-reviewed publications
      • Webinars
      • R&D Blog post
      • Whitepapers/Executive Summary
      • Poster
      • View all
    View all Cell & Gene offerings
    View all Bioscience Products
    View all locations
  • Capsules & Health Ingredients
    • Pharmaceutical Solutions
    • Nutraceutical Solutions
  • Contact
  • Trending Topics
    Webinar: Powder to Particles with Jet Milling
    Stability of Dry Powder Inhaler Protein Formulations
Trending Topics
Webinar: Powder to Particles with Jet Milling
Stability of Dry Powder Inhaler Protein Formulations
Biologics
Biologics
Modalities
  • Mammalian
  • Microbial
  • ADCs / Bioconjugates
  • mRNA / LNP
  • Drug Product
Technologies & Products
  • Expression Technologies
  • Discovery Products
  • Bioprocessing Products
Discovery and Preclinical
  • Early De-risking & Optimization
  • Cell Line & Strain Development
  • Process Development & Optimization
  • Analytical Development
  • Formulation Development
  • Non-GMP Manufacture
Clinical and Commercial
  • Process Development & Optimization
  • Formulation Optimization
  • cGMP Drug Substance Manufacture
  • cGMP Drug Product Manufacture
Back
Small Molecules
Small Molecules
Services
  • Drug Substance (API)
  • Particle Engineering
  • Drug Product
Technologies
  • Highly Potent API (HPAPI)
  • ADCs
  • Spray Dried Dispersions
  • Micronization & Jet Milling
  • Inhaled Delivery (DPI)
Solutions
  • Early Phase API
  • Commercial Production API
  • Bioavailability Enhancement
  • Integrated Offerings
Knowledge Center
  • Webinars
  • Presentations
  • Publications
  • Meet the Experts
  • View all
Back
Cell & Gene
Cell & Gene
Services
  • Process Development
  • cGMP Manufacturing
  • Regulatory Consulting
  • Bioassay Services
  • Tissue Acquisition
Modalities
  • Autologous
  • Allogeneic
  • Viral Vectors
  • iPSCs
  • Exosomes
Technologies
  • MODA® Platform
  • Cocoon® Platform
  • Nucleofector® Technology
  • TheraPEAK® Media
  • Endotoxin and Pyrogen Testing
Knowledge Center
  • Peer-reviewed publications
  • Webinars
  • R&D Blog post
  • Whitepapers/Executive Summary
  • Poster
  • View all
Back
Capsules & Health Ingredients
Capsules & Health Ingredients
Pharmaceutical Solutions
Nutraceutical Solutions
Back
Contact
Back
  • Home
  • Knowledge Center
  • Meet the Experts
  • Maurits Janssen, Ph.D.
Drug Substance/HPAPI

Maurits Janssen, Ph.D.

Maurits Janssen serves as Executive Director, Strategic Business Development, for the Small Molecules Division at Lonza and is located in Basel, Switzerland. Maurits has more than 25 years of experience in the chemical and pharmaceutical industries and has worked on a broad portfolio of technologies, focusing on the custom development and manufacturing of active pharmaceutical ingredients (CDMO). His expertise includes chemical and biological custom development & manufacturing from early-stage to late-phase & commercial under current Good Manufacturing Practice (cGMP) conditions. Experience includes highly potent active pharmaceutical ingredients (HPAPIs), cytotoxic compounds, peptides and conjugates, as well as a variety of products produced using mammalian or microbial platform technologies. In addition to Lonza, he has worked for Siegfried, RohnerChem, and Sigma Aldrich, holding positions of increasing responsibility in management consulting, marketing and sales, and research and development functions. Maurits earned his Ph.D. in Organic Chemistry from Utrecht University, The Netherlands.
Content by this expert

Recently published by Maurits

KC Whitepaper thumbnail
Whitepaper/Executive Summary
Requirements for Fully Integrated Offerings in a HPAPI and Cytotoxic Environment
The development of drug products based on potent compounds can be challenging, plus complications...
HPAPI, SMM
Whitepaper/Executive Summary
The Rise of HPAPI Molecules - Trends in Highly Potent API Manufacturing
Highly potent active pharmaceutical ingredients are increasing in pharma pipelines. Lonza offers all...
KC Whitepaper thumbnail
Whitepaper/Executive Summary
JAPANESE - Requirements for fully-integrated service-offerings in a HPAPI and cytotoxic environment
Drug-product development for highly potent APIs (HPAPIs) is challenging. This webinar provides best...
KC Whitepaper thumbnail
Whitepaper/Executive Summary
Best Practices for Highly Potent API (HPAPI) Development and Manufacturing
Drug-product development for highly potent APIs (HPAPIs) is challenging. This executive summary in...
Ways to Contact
  • Contact Us
  • Regulatory Support
  • Locations
  • Site Tours
  • Partnering with Us
Resources
  • Knowledge Center
  • Meet the Experts
  • Upcoming Events
Terms & Conditions
  • Terms and Conditions
  • Legal Disclaimer
  • Privacy Policy
  • California CCPA Notice
  • Transparency in Coverage
Lonza.com
  • Company Overview
  • News & Media
  • Investor Relations
  • Sustainability
  • Careers
  • Sitemap
© 2023 Lonza. All rights reserved.